A useful design utilizing the information fraction in a group sequential clinical trial with censored survival data

审查(临床试验) 威布尔分布 统计 样本量测定 中期分析 提前停车 数学 临时的 对数秩检验 威尔科克森符号秩检验 临床试验 生存分析 计算机科学 医学 曼惠特尼U检验 内科学 人工智能 历史 人工神经网络 考古
作者
Chih-Yuan Hsu,Chen-Hsin Chen,Ken-Ning Hsu,Ya-Hung Lu
出处
期刊:Biometrics [Oxford University Press]
被引量:1
标识
DOI:10.1111/biom.12925
摘要

Lan and DeMets (1983) proposed the alpha spending function for group sequential trials to permit the use of unspecified frequencies and timings of interim analyses in the trial design. Regarding a trial with censored time to endpoint, Lan and DeMets (1989) later defined information time at an interim analysis in a maximum duration trial. To compare two survival curves utilizing such a design, information times for group sequential logrank and Wilcoxon-type statistics have been developed by assuming that the survival time follows an exponential distribution or a Weibull distribution without considering the censoring distribution. To better address the practical concerns inherent in clinical trials with survival endpoints, we present a new approach to adequately design a group sequential trial using the Harrington-Fleming (1982) test based on our proposed information fractions by assuming the censoring distribution depends on the patient's accrual time according to various entry distributions and by extending the underlying survival distribution to the generalized gamma distribution. We also determine associated sample sizes, expected number of events and expected stopping time. Two phase III trials of non-small-cell lung cancer originally designed using fixed-sample tests are utilized to illustrate the potential advantages of using a group sequential design with the proposed approach. This enhanced method facilitates the design and analysis of group sequential clinical trials studying survival endpoints by increasing implemental flexibility.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
那时花开发布了新的文献求助10
2秒前
3秒前
5秒前
艾斯完成签到 ,获得积分10
5秒前
所所应助科研通管家采纳,获得10
5秒前
5秒前
Orange应助科研通管家采纳,获得10
6秒前
6秒前
FashionBoy应助科研通管家采纳,获得10
6秒前
天天快乐应助科研通管家采纳,获得10
6秒前
深情安青应助科研通管家采纳,获得10
6秒前
科目三应助科研通管家采纳,获得10
6秒前
英俊的铭应助科研通管家采纳,获得10
6秒前
科研通AI5应助科研通管家采纳,获得10
6秒前
大个应助科研通管家采纳,获得10
6秒前
NexusExplorer应助科研通管家采纳,获得10
6秒前
香蕉觅云应助科研通管家采纳,获得10
6秒前
量子星尘发布了新的文献求助150
7秒前
Xiaoxiao应助科研通管家采纳,获得10
7秒前
浮游应助科研通管家采纳,获得10
7秒前
小青椒应助科研通管家采纳,获得20
7秒前
7秒前
带头大哥应助科研通管家采纳,获得150
7秒前
7秒前
7秒前
7秒前
王来敏发布了新的文献求助10
8秒前
英俊的铭应助周周采纳,获得10
10秒前
healer发布了新的文献求助10
11秒前
zytccab发布了新的文献求助10
12秒前
13秒前
13秒前
14秒前
小二郎应助李家静采纳,获得10
14秒前
冉冉完成签到,获得积分20
14秒前
16秒前
16秒前
dddd完成签到,获得积分20
17秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
Lloyd's Register of Shipping's Approach to the Control of Incidents of Brittle Fracture in Ship Structures 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5144545
求助须知:如何正确求助?哪些是违规求助? 4342237
关于积分的说明 13522560
捐赠科研通 4182757
什么是DOI,文献DOI怎么找? 2293639
邀请新用户注册赠送积分活动 1294207
关于科研通互助平台的介绍 1236955